Inhibition of the growth of patient-derived pancreatic cancer xenografts with the MEK inhibitor trametinib is augmented by combined treatment with the epidermal growth factor receptor/HER2 inhibitor lapatinib. [electronic resource]
Producer: 20130924Description: 143-55 p. digitalISSN:- 1476-5586
- Animals
- Antineoplastic Agents -- administration & dosage
- Cell Line, Tumor
- ErbB Receptors -- antagonists & inhibitors
- Humans
- Lapatinib
- MAP Kinase Kinase Kinases -- antagonists & inhibitors
- MAP Kinase Signaling System -- genetics
- Mice
- Neoplasm Transplantation
- Pancreatic Neoplasms -- drug therapy
- Phosphorylation -- drug effects
- Protein Kinase Inhibitors -- administration & dosage
- Pyridones -- administration & dosage
- Pyrimidinones -- administration & dosage
- Quinazolines -- administration & dosage
- Receptor, ErbB-2 -- antagonists & inhibitors
- Signal Transduction -- drug effects
No physical items for this record
Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.